Viropharma

Viropharma predicts that sales of its Cinryze, a treatment to prevent a dangerous swelling of the face, will increase from $95 million last year to $350 million several years from now.

The World's Most Expensive Drugs 2010

Because Vancocin was the only drug on the market that treated this disease, Viropharma had been able to raise prices seriously after it bought the drug from Lilly.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

Because Vancocin was the only drug on the market that treated this disease, Viropharma had been able to raise prices seriously after it bought the drug from Lilly.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

I got behind Viropharma for the same reason that a handful of analysts on the Street had liked the stock.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

Now, as I write this book in August 2006, Viropharma has been treading water under $10 for a couple of months.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

I got behind Viropharma for the same reason that a handful of analysts on the Street had liked the stock.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

Now, as I write this book in August 2006, Viropharma has been treading water under $10 for a couple of months.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

Now, as I write this book in August 2006, Viropharma has been treading water under $10 for a couple of months.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

Because Vancocin was the only drug on the market that treated this disease, Viropharma had been able to raise prices seriously after it bought the drug from Lilly.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006

I got behind Viropharma for the same reason that a handful of analysts on the Street had liked the stock.

Jim Cramer's Mad Money James J. Cramer with Cliff Mason 2006